IMI INTERNATIONAL MEDICAL INNOVATIONS INC Form 6-K May 10, 2005

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

Dated May 10, 2005

IMI International Medical Innovations Inc. Commission File Number 1-31360 615-4211 Yonge Street Toronto, Ontario M2P 2A9 CANADA

(Address of Principal Executive Offices)

Indicate by check mark whether the reg	istrant files or will file	e annual reports under cover Form 20-F or Form 40-F
	Form 20-F ý	Form 40-F o
Indicate by check mark if the registrant 101(b)(1):	is submitting the Forr	m 6-K in paper as permitted by Regulation S-T Rule
Note: Regulation S-T Rule 101(b)(1) or provide an attached annual report to sec	• 1	ssion in paper of a Form 6-K if submitted solely to
Indicate by check mark if the registrant 101(b)(7):	is submitting the Forr	m 6-K in paper as permitted by Regulation S-T Rule

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnish furnishing the information to the Commission	_			
	Yes "	No ý		
If "Yes" is marked, indicate below the file	e number assign	ned to the registrant in co	onnection with Rule 12g3-2(b): 82	-

IMI International Medical Innovations Inc.

Form 6-K

On May 10, 2005, the Corporation issued a press release announcing a major clinical trial in the life insurance testing industry using IMI's non-invasive cardiovascular risk assessment technology. The study, called PREPARE (PREVU* Predicts Atherosclerosis Risk and Events) is expected to begin in the second quarter of 2005. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMI International Medical Innovations Inc.

By: /s/ Ronald G. Hosking

Ronald G. Hosking

Vice President and Chief Financial Officer

Date: May 10, 2005

EXHIBIT INDEX

Exhibit

Description Number

The Registrant's Press Release Dated May 10, 2005 99.1